Denileukin diftitox
- Generic Name
- Denileukin diftitox
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 173146-27-5
- Unique Ingredient Identifier
- 25E79B5CTM
- Background
A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.
- Indication
For treatment of cutaneous T-cell lymphoma
- Associated Conditions
- Cutaneous T-Cell Lymphoma (CTCL)
- Associated Therapies
- -
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT01127451
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 15
- Registration Number
- NCT01106950
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Denileukine Diftitox for Relapsed ALCL
- Conditions
- Interventions
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Columbia University
- Registration Number
- NCT00801918
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
- Conditions
- Interventions
- Drug: GemcitabineDrug: NavelbineDrug: Doxorubicin Hydrochloride Liposome InjectionDrug: Granulocyte-colony stimulating factor (G-CSF)Drug: PegfilgrastimDrug: CyclophosphamideDrug: VincristineDrug: LeucovorinDrug: MethotrexateDrug: Doxorubicin HydrochlorideDrug: CytarabineDrug: EtoposideDrug: CarmustineDrug: Denileukin diftitox
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 21
- Registration Number
- NCT00632827
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
Phase II Trial of Ontak With Metastatic Melanoma
- First Posted Date
- 2006-03-07
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- James Graham Brown Cancer Center
- Target Recruit Count
- 69
- Registration Number
- NCT00299689
- Locations
- 🇺🇸
James Graham Brown Cancer Center, Univ. of Louisville, Louisville, Kentucky, United States
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
- Conditions
- Interventions
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 180
- Registration Number
- NCT00224874
- Locations
- 🇺🇸
DFCI/Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Washington University/Barnes Jewish Hospital, Saint Louis, Missouri, United States
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT00211185
- Locations
- 🇺🇸
Hematology Oncology Associates of IL, Chicago, Illinois, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.